GlassScriptPhysician profile
Lauren Jendraszek
NPI 1841502887
$39,662.57
in general payments reported to CMS, 2019-2025
35 companies · $5,289 in 2025
The $5,289 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14K · 2022: $9,342 · 2023: $8,607 · 2024: $2,916 · 2025: $5,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,131 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,099 · Travel and Lodging: $1,661 · Honoraria: $1,000 · Consulting Fee: $921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,131.33 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,098.75 |
| Travel and Lodging | $1,660.93 |
| Honoraria | $1,000.00 |
| Consulting Fee | $921.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $24,189.97 | 2021-2025 | |
| Upsher-Smith Laboratories LLC | $2,503.36 | 2021-2023 | |
| Tonix Medicines, INC. | $1,950.60 | 2023-2025 | Zembrace Symtouch |
| Teva Pharmaceuticals USA, INC. | $1,862.28 | 2021-2025 | Ajovy, Austedo Xr |
| Allergan, INC. | $1,431.68 | 2021 | |
| Currax Pharmaceuticals LLC | $1,012.28 | 2021-2025 | Onzetra Xsail, Contrave |
| Amgen INC. | $938.22 | 2021-2024 | Aimovig |
| Lilly USA, LLC | $922.49 | 2021-2025 | Emgality, Reyvow, Zepbound |
| Biohaven Pharmaceuticals, INC. | $781.41 | 2021 | |
| Lundbeck LLC | $579.25 | 2021-2025 | Vyepti |
| Impel Pharmaceuticals INC. | $562.70 | 2022-2023 | Trudhesa |
| Biohaven Pharmaceutical Holding Company LTD. | $361.68 | 2022 | |
| Pfizer INC. | $347.20 | 2021-2025 | |
| Scilex Pharmaceuticals INC. | $284.07 | 2023-2025 | Ztlido, Elyxyb |
| Ucb, INC. | $275.73 | 2021-2025 | Nayzilam, Briviact |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $275.22 | 2021 | |
| Axsome Therapeutics, INC. | $213.17 | 2023-2025 | Symbravo, Auvelity |
| Collegium Pharmaceutical, INC. | $160.12 | 2022 | |
| Eisai INC. | $113.91 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $111.88 | 2021 | |
| Impel Pharmaceuticals LLC | $109.33 | 2024-2025 | Trudhesa |
| Novocure INC. | $96.77 | 2021-2023 | Optune |
| Novo Nordisk INC | $69.65 | 2023-2025 | Wegovy |
| Arbor Pharmaceuticals, INC. | $63.93 | 2021 | |
| Supernus Pharmaceuticals, INC. | $59.33 | 2021-2022 | |
| Sk Life Science, INC. | $55.81 | 2021-2023 | |
| Ibsa Pharma INC. | $51.44 | 2024-2025 | Tirosint, Licart, Flector |
| Amneal Pharmaceuticals LLC | $45.37 | 2024-2025 | Brekiya, Avastin |
| Si-Bone, INC. | $42.19 | 2021 | |
| Springworks Therapeutics, INC. | $39.83 | 2025 | Gomekli |
| Azurity Pharmaceuticals, INC. | $37.42 | 2023 | Eprontia |
| Averitas Pharma INC. | $36.02 | 2024-2025 | Qutenza |
| Catalyst Pharmaceuticals, INC. | $28.12 | 2023 | Firdapse |
| Ge Healthcare | $25.71 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $24.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Jendraszek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.